Market Size of Brazil Diabetes Care Devices Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.06 Billion |
| Market Size (2029) | USD 1.37 Billion |
| CAGR (2024 - 2029) | > 5.62 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Brazil Diabetes Care Devices Market Analysis
The Brazil Diabetes Care Devices Market size is estimated at USD 1.06 billion in 2024, and is expected to reach USD 1.37 billion by 2029, growing at a CAGR of greater than 5.62% during the forecast period (2024-2029).
The COVID-19 pandemic has had a notable impact on the diabetes care devices market. Diabetes is a chronic condition demanding self-management and care, which involves regular attention to food, physical activity, blood sugar monitoring, and the use of medications. People with chronic diseases such as diabetes mellitus and obesity have a worse prognosis of COVID-19. Diabetic people are twice more likely to have their comorbid conditions worsened, and consequently to die. The healthcare system must be better organized for more severe cases of COVID-19 as studies suggest that inadequate glycemic control increases the risk of undesired outcomes in diabetic patients with SARS-CoV-2 infection. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with COVID-19 have underlined the importance of diabetes care devices.
According to IDF Diabetes Atlas 2021, 15.7 million adults about 10.5% are currently living with diabetes in Brazil - or one in ten adults. The cost of diabetes-related health expenditure in Brazil is the third highest in the world, at 42.9 billion USD. In addition, 18 million adults around 11.9% have Impaired Glucose Tolerance which places them at high risk of developing type 2 diabetes. 32% of people living with diabetes in Brazil are undiagnosed. Additional data on glycaemic control in Brazil show that only 25% met the therapeutic goal of glycated haemoglobin (HbA1c) <7% before the pandemic, as recommended by the Brazilian Diabetes Society (SBD).
Brazil has implemented a set of reforms over the past to improve the distribution of doctors, develop new forms of service organization, introduce new financing models, and implement a range of quality improvement initiatives and policy frameworks to overcome risk factors such as obesity and emerging pandemic threats. This also highlights opportunities for continuing and expanding innovations in the delivery of diabetes care and the use of diabetes technology.
